- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02568813
Epilepsy and Mood Regulation Disorder in Children (EPILETRE)
Epilepsy and Mood Regulation Disorders: a Prospective and Longitudinal Study in Children With Newly Diagnosed Epilepsy
Epilepsy is a multifaceted disorder and a major public health problem. In addition to recurrent and unpredictable seizures, abnormalities in psychiatric status, cognition and social-adaptive behaviors are potential major sources of disability in children and adults with epilepsy disorders. Recent studies have unequivocally documented raised psychiatric comorbidities in children with epilepsy, particularly emotional regulation disorders such as depression and anxiety, as compared to both the general population and the children with other medical disorders, neurological and non-neurological. A prevalence of 12% to 35% has been reported, compared to 3-8% in the general population.
Major advances have begun to uncover the potential mediators of emotional regulation disorders and social comorbidities in epilepsy, but important gaps remain in the early detection, treatment and prevention of these disorders. A very small number of investigations have examined children with epilepsy at or near the time of diagnosis. This is a time during which the effects of chronic epilepsy, potential averse social effects of epilepsy, and other complicating aetiological effects are minimized.
Epilepsy syndromes provide a useful framework for considering the risk and type of emotional dysregulation comorbidities. But variability within and across syndromes needs to be taken into account thus requiring a strict phenotyping by specialists in the filed of pediatric epileptology. Retrospective studies, usually including patients with chronic epilepsies and suffering from a mixed spectrum of epilepsy syndromes introduce biases leading to rather disparate findings.
Are such disorders the result of common physiopathological mechanisms, which precede the development of the epilepsy? The link between an underlying brain disorder and psychiatric comorbidities has emerged in recent literature, with evidence based on studies in adults, suggesting bidirectional relations between epilepsy and neurobehavioural comorbidities. Emotional regulation disorders can follow the onset of epilepsy, but they can also precede it, thus serving as a possible risk factor. The clinical implication of such a bidirectional association is that neurobehavioural comorbidities might be present at diagnosis and even before epilepsy onset. There is a need for greater understanding of the causes of these conditions in younger people.
The degree to which specific epilepsy syndromes are associated with the relative risk of emotional dysregulation disorders in children with new- or recent-onset (within six months prior to enrolment) has rarely been comprehensively examined and represents the focus of the current investigation.
The investigators study will be based on a prospectively recruited cohort of 280 children/adolescents with recently diagnosed epilepsy. All participating centres dispose of the necessary competences for a precise diagnosis of the epilepsy syndromes and the tools for a per case appropriate aetiology screening. Following a first seizure children are usually first examined at hospital based emergency departments. Prompt referral to the epilepsy teams participating at the present study will significantly reduce the population biases and shortcuts encountered in studies that recruited patients with chronic epilepsy followed in tertiary care epilepsy units.
The investigators expect their results to provide a greater understanding of both the shared and the unique features of emotional regulation disorders, in relation to specific epilepsy categories defined on the basis of the underlying physiopathological mechanisms.
Such knowledge will also assist clinicians and families in the planning of both diagnosis and management resources.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Alexis ARZIMANOGLOU, Pr
- Phone Number: +33 (0)4 27 85 77 04
- Email: aarzimanoglou@orange.fr
Study Contact Backup
- Name: Agathe LAURENT,, PhD
- Phone Number: +33 (0)6 61 60 11 30
- Email: agathelaurent1977@gmail.com
Study Locations
-
-
Rhône
-
Bron, Rhône, France, 69500
- Recruiting
- Hôpital Femme Mère Enfant
-
Contact:
- Alexis ARZIMANOGLOU, Pr
- Phone Number: +33 (0)4 27 85 77 04
- Email: aarzimanoglou@orange.fr
-
Contact:
- Agathe LAURENT, PhD
- Phone Number: +33 (0)6 61 60 11 30
- Email: agathelaurent1977@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- one of the following 3 epilepsy categories (focal structural epilepsy, with or without (MRI-negative) detectable cerebral lesion; focal idiopathic (genetic) epilepsy; generalized idiopathic (genetic) epilepsy).
- Onset of epilepsy within the 6 months from enrolment.
- Patients whose eventual antiepileptic drug treatments were not modified in the months preceding the neuropsychological and psychiatric evaluations.
- Patients who give their consent to participate in the study and whose legal guardians have agreed to sign the written consent form.
Exclusion Criteria:
- Patients younger than 5 years and 11 months or older than 15 years and 6 months.
- Patients with a diagnosis of epilepsy, other than the types defined above.
- Cognitive impairment, defined as a score of <70, based on WISC-IV verbal comprehension and perceptual reasoning scales.
- Children with a confirmed diagnosis of a psychiatric disorder, other than those studied.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: SUPPORTIVE_CARE
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Scales passation
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of children with new- or recent-onset epilepsy with a pathological score in a least one of the 3 scales
Time Frame: 18 months
|
The 3 scales are MDI-C ; R-CMAS and Kochman scale :
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlate pathological scores obtained with the type of epilepsy
Time Frame: 18 months
|
The same scoring system as for the primary end point will be used Type of epilepsy :
|
18 months
|
Correlate pathological scores with the progression of epilepsy disease
Time Frame: 18 months
|
The same scoring system as for the primary end point will be used to evaluate the development, or progression, of emotional regulation disorders after 18 months of follow-up (constituted epilepsy); In each types of epilepsy, progression of the disease will be assessed by :
|
18 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013-834
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epilepsy
-
NaviFUS CorporationTaipei Veterans General Hospital, TaiwanCompletedDrug Resistant Epilepsy | Epilepsy, Drug Resistant | Intractable Epilepsy | Refractory Epilepsy | Drug Refractory Epilepsy | Epilepsy, Drug Refractory | Epilepsy, Intractable | Medication Resistant EpilepsyTaiwan
-
Great Ormond Street Hospital for Children NHS Foundation...Active, not recruitingEpilepsies, Partial | Intractable Epilepsy | Focal Epilepsy | Refractory Epilepsy | Epilepsy Intractable | Epilepsy in Children | Epilepsy, FocalUnited Kingdom
-
University of British ColumbiaTerminatedJuvenile Myoclonic Epilepsy | Childhood Absence Epilepsy | Juvenile Absence EpilepsyCanada
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruiting
-
Neuroelectrics CorporationRecruitingEpilepsy | Seizures | Refractory Epilepsy | Epilepsy, Tonic-Clonic | Epilepsy in Children | Seizures, Focal | Focal SeizureSpain, United States, France, Belgium
-
Oslo University HospitalCompletedEpilepsy | Generalized Epilepsy | Focal EpilepsyNorway
-
UCB Pharma SACompletedEpilepsy, Tonic-clonicPoland, Sweden, Hungary, Czechia
-
UCB PharmaCompletedEpilepsy, Tonic-clonic
-
University Hospital, LilleUnknownFocal Epilepsy | Epilepsy IntractableFrance
-
Xuanwu Hospital, BeijingPeking University; Beijing Tiantan Hospital; Qilu Hospital of Shandong University and other collaboratorsNot yet recruitingEpilepsy, Drug ResistantChina
Clinical Trials on Multiscore Depression Inventory for Children scale
-
NYU Langone HealthCompleted
-
Assiut UniversityCompleted
-
Northwell HealthTerminated
-
Assiut UniversityNot yet recruiting
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingConduct Disorder | Autism-Spectrum DisorderSwitzerland
-
University of FloridaCompleted
-
Children's Mercy Hospital Kansas CityCompletedDepression | Insulin ResistanceUnited States
-
Sheba Medical CenterUniversity of HaifaCompleted
-
Konya Beyhekim Training and Research HospitalCompleted
-
Fondation LenvalActive, not recruitingCOVID-19 | Psychiatric Disorder | Eating Disorders in AdolescenceFrance